gdc-0994
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 21, 2013 (NCT01875705)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1- Mol. weight
- 440.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544964 ↗
Also known as
- gdc-0994
- gdc-0994
- gdc-0994
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01875705 | Phase 1 | Jun 21, 2013 | Genentech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1